Case 3: Faricimab in a neovascular nAMD patient with persistent fluid
Dr. Khanani discusses how switching to faricimab helped resolve persistent intraretinal and subretinal fluid in a patient and extended treatment intervals leading to decreased patient burden.
Sponsored by Roche
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
